Raymond James & Associates’s iShares Biotechnology ETF IBB Stock Holding History

Raymond James & Associates’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$25.6M	Sell	176,121 -13,645	-7%	-$1.97M	0.02%	694
2024 Q2	$26M	Buy	189,766 +7,931	+4%	+$1.06M	0.02%	654
2024 Q1	$25M	Buy	181,835 +9,073	+5%	+$1.24M	0.02%	677
2023 Q4	$23.5M	Sell	172,762 -15,732	-8%	-$1.92M	0.02%	668
2023 Q3	$23.1M	Sell	188,494 -3,808	-2%	-$484K	0.02%	618
2023 Q2	$24.4M	Sell	192,302 -10,869	-5%	-$1.41M	0.02%	612
2023 Q1	$26.2M	Buy	203,171 +5,799	+3%	+$759K	0.02%	579
2022 Q4	$25.9M	Buy	197,372 +17,857	+10%	+$2.31M	0.02%	557
2022 Q3	$21M	Buy	179,515 +26,224	+17%	+$3.26M	0.02%	601
2022 Q2	$18M	Sell	153,291 -17,502	-10%	-$2.08M	0.02%	668
2022 Q1	$22.3M	Sell	170,793 -11,697	-6%	-$1.52M	0.02%	645
2021 Q4	$27.9M	Sell	182,490 -1,953	-1%	-$302K	0.02%	592
2021 Q3	$29.8M	Buy	184,443 +12,630	+7%	+$2.13M	0.03%	522
2021 Q2	$28.1M	Sell	171,813 -15,846	-8%	-$2.44M	0.03%	543
2021 Q1	$28.3M	Sell	187,659 -29,886	-14%	-$4.75M	0.03%	514
2020 Q4	$33M	Buy	217,545 +18,724	+9%	+$2.68M	0.04%	416
2020 Q3	$26.9M	Sell	198,821 -9,753	-5%	-$1.32M	0.03%	437
2020 Q2	$28.5M	Buy	208,574 +66,289	+47%	+$8.45M	0.04%	390
2020 Q1	$15.3M	Sell	142,285 -30,061	-17%	-$3.46M	0.02%	553
2019 Q4	$20.8M	Buy	172,346 +21,102	+14%	+$2.35M	0.03%	563
2019 Q3	$15M	Sell	151,244 -36,857	-20%	-$3.86M	0.02%	672
2019 Q2	$20.5M	Sell	188,101 -17,114	-8%	-$1.82M	0.03%	526
2019 Q1	$22.9M	Sell	205,215 -3,120	-1%	-$342K	0.03%	470
2018 Q4	$20.1M	Sell	208,335 -52,828	-20%	-$5.61M	0.04%	471
2018 Q3	$31.8M	Buy	261,163 +26,921	+11%	+$3.17M	0.05%	362
2018 Q2	$25.7M	Sell	234,242 -50,156	-18%	-$5.36M	0.04%	405
2018 Q1	$30.4M	Buy	284,398 +5,780	+2%	+$641K	0.05%	326
2017 Q4	$29.8M	Buy	278,618 +26,303	+10%	+$2.81M	0.05%	329
2017 Q3	$28.1M	Buy	252,315 +19,878	+9%	+$2.12M	0.06%	322
2017 Q2	$24M	Buy	232,437 +46,932	+25%	+$4.62M	0.05%	350
2017 Q1	$18.1M	Sell	185,505 -115,275	-38%	-$11M	0.04%	431
2016 Q4	$26.6M	Buy	300,780 +46,671	+18%	+$4.25M	0.07%	284
2016 Q3	$24.5M	Buy	254,109 +119,511	+89%	+$11.4M	0.07%	286
2016 Q2	$11.5M	Buy	134,598 +48,363	+56%	+$4.34M	0.04%	487
2016 Q1	$7.5M	Sell	86,235 -70,704	-45%	-$6.32M	0.03%	636
2015 Q4	$17.7M	Sell	156,939 -12,339	-7%	-$1.34M	0.06%	333
2015 Q3	$17.1M	Sell	169,278 -12,627	-7%	-$1.51M	0.07%	304
2015 Q2	$22.4M	Buy	181,905 +906	+0.5%	+$108K	0.09%	270
2015 Q1	$20.7M	Buy	180,999 +28,632	+19%	+$3.16M	0.09%	244
2014 Q4	$15.4M	Buy	152,367 +77,583	+104%	+$7.54M	0.08%	288
2014 Q3	$6.82M	Sell	74,784 -11,970	-14%	-$1.05M	0.04%	491
2014 Q2	$7.43M	Buy	86,754 +9,195	+12%	+$724K	0.05%	456
2014 Q1	$6.11M	Buy	77,559 +14,754	+23%	+$1.23M	0.04%	488
2013 Q4	$4.75M	Buy	62,805 +3,840	+7%	+$272K	0.04%	555
2013 Q3	$4.12M	Buy	58,965 +8,508	+17%	+$557K	0.04%	551
2013 Q2	$2.92M	Buy	+50,457	New	+$2.92M	0.03%	636

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Raymond James & Associates's IBB Position: Q3 2024 in Review

Raymond James & Associates reduced its iShares Biotechnology ETF (IBB) stake by 7.2% in Q3 2024, selling an estimated $1.97M and leaving 176,121 shares worth $25.6M. The position accounts for 0.02% of the portfolio, ranked #694.

Raymond James & Associates first reported a position in IBB in Q2 2013 and has held it in 46 quarters since. The position peaked at $33M in Q4 2020. 894 funds tracked by Wall St. Rank hold IBB as of Q3 2024.

Raymond James & Associates held 176,121 shares of iShares Biotechnology ETF worth $25.6M as of Q3 2024.
Raymond James & Associates sold 13,645 iShares Biotechnology ETF shares in Q3 2024, an estimated $1.97M.
iShares Biotechnology ETF made up 0.02% of Raymond James & Associates's portfolio in Q3 2024, its #694 holding.
Raymond James & Associates first reported a position in iShares Biotechnology ETF in Q2 2013 and has held it in 46 quarters since.
Raymond James & Associates's iShares Biotechnology ETF position peaked at $33M in Q4 2020.
894 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.